Buyer Appetite Might Appeal To GI Device Investors
By
Tom Salemi / Email the Author / START-UP December 2011, Vol. 16, No. 11
Valuation Watch / Word Count: 655 / Article # 2011900265
Executive Summary
A long-time darling of venture capital, the gastrointestinal sector has yet to meet expectation of VCs who wagered on technologies to treat gastroesophageal reflux disease, Barrett’s esophagus and even obesity. But some notable acquisitions, including Covidien’s purchase of privately held Barrx, may present a ray of hope for investors in GI companies.
$35.00
Buy Now
For $35.00, purchase this 655-word article and receive immediate online access. 100% Satisfaction Guarantee.
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.